Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.

Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX; NIH Rare Lung Disease Consortium.

Eur Respir J. 2019 Apr 4;53(4). pii: 1802066. doi: 10.1183/13993003.02066-2018. Print 2019 Apr.

PMID:
30846465
2.

Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis.

Gopalakrishnan V, Yao J, Steagall WK, Avila NA, Taveira-DaSilva AM, Stylianou M, Chen MY, Moss J.

Chest. 2019 May;155(5):962-971. doi: 10.1016/j.chest.2019.01.004. Epub 2019 Jan 17.

PMID:
30660784
3.

Expanding the phenotype of COPA syndrome: a kindred with typical and atypical features.

Taveira-DaSilva AM, Markello TC, Kleiner DE, Jones AM, Groden C, Macnamara E, Yokoyama T, Gahl WA, Gochuico BR, Moss J.

J Med Genet. 2018 Nov 1. pii: jmedgenet-2018-105560. doi: 10.1136/jmedgenet-2018-105560. [Epub ahead of print]

4.

The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis.

Gupta N, Lee HS, Ryu JH, Taveira-DaSilva AM, Beck GJ, Lee JC, McCarthy K, Finlay GA, Brown KK, Ruoss SJ, Avila NA, Moss J, McCormack FX; NHLBI LAM Registry Group.

Chest. 2019 Feb;155(2):288-296. doi: 10.1016/j.chest.2018.06.016. Epub 2018 Jun 22.

PMID:
29940164
5.

Rates of change in FEV1 and DLCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients.

Taveira-DaSilva AM, Julien-Williams P, Jones AM, Stylianou M, Moss J.

Eur Respir J. 2018 Apr 19;51(4). pii: 1702258. doi: 10.1183/13993003.02258-2017. Print 2018 Apr.

PMID:
29519926
6.

Mounier-Kuhn Syndrome Mimicking Lymphangioleiomyomatosis.

Pacheco GG, Jones AM, Yao J, Kleiner DE, Taveira-DaSilva AM, Moss J.

Chest. 2018 Feb;153(2):e19-e23. doi: 10.1016/j.chest.2017.10.024.

7.

Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline.

Gupta N, Finlay GA, Kotloff RM, Strange C, Wilson KC, Young LR, Taveira-DaSilva AM, Johnson SR, Cottin V, Sahn SA, Ryu JH, Seyama K, Inoue Y, Downey GP, Han MK, Colby TV, Wikenheiser-Brokamp KA, Meyer CA, Smith K, Moss J, McCormack FX; ATS Assembly on Clinical Problems.

Am J Respir Crit Care Med. 2017 Nov 15;196(10):1337-1348. doi: 10.1164/rccm.201709-1965ST.

8.

Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.

Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J.

Chest. 2018 Jan;153(1):124-132. doi: 10.1016/j.chest.2017.05.012. Epub 2017 May 19.

9.

EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Taveira-DaSilva AM, Moss J.

Expert Opin Orphan Drugs. 2016;4(4):369-378. Epub 2016 Mar 7.

10.

Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, Steagall WK, Johnson SR, Sahn SA, Ryu JH, Strange C, Seyama K, Sullivan EJ, Kotloff RM, Downey GP, Chapman JT, Han MK, D'Armiento JM, Inoue Y, Henske EP, Bissler JJ, Colby TV, Kinder BW, Wikenheiser-Brokamp KA, Brown KK, Cordier JF, Meyer C, Cottin V, Brozek JL, Smith K, Wilson KC, Moss J; ATS/JRS Committee on Lymphangioleiomyomatosis.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):748-61. doi: 10.1164/rccm.201607-1384ST.

11.

Benign Metastasizing Leiomyoma.

Pacheco-Rodriguez G, Taveira-DaSilva AM, Moss J.

Clin Chest Med. 2016 Sep;37(3):589-95. doi: 10.1016/j.ccm.2016.04.019. Epub 2016 Jun 25. Review.

PMID:
27514603
12.

Lymphangioleiomyomatosis.

Johnson SR, Taveira-DaSilva AM, Moss J.

Clin Chest Med. 2016 Sep;37(3):389-403. doi: 10.1016/j.ccm.2016.04.002. Review.

PMID:
27514586
13.

Incidence of Pneumothorax in Patients With Lymphangioleiomyomatosis Undergoing Pulmonary Function and Exercise Testing.

Taveira-DaSilva AM, Julien-Williams P, Jones AM, Moss J.

Chest. 2016 Jul;150(1):e5-8. doi: 10.1016/j.chest.2015.10.071.

14.

Increased consumption and vasodilatory effect of nitrite during exercise.

Hon YY, Lin EE, Tian X, Yang Y, Sun H, Swenson ER, Taveira-Dasilva AM, Gladwin MT, Machado RF.

Am J Physiol Lung Cell Mol Physiol. 2016 Feb 15;310(4):L354-64. doi: 10.1152/ajplung.00081.2015. Epub 2015 Dec 18.

15.

Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

Taveira-DaSilva AM, Jones AM, Julien-Williams P, Shawker T, Glasgow CG, Stylianou M, Moss J.

Chest. 2015 Oct;148(4):1027-1033. doi: 10.1378/chest.15-0456.

16.

Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.

Taveira-DaSilva AM, Moss J.

Clin Epidemiol. 2015 Apr 7;7:249-57. doi: 10.2147/CLEP.S50780. eCollection 2015. Review.

17.

Management of lymphangioleiomyomatosis.

Taveira-DaSilva AM, Moss J.

F1000Prime Rep. 2014 Dec 1;6:116. doi: 10.12703/P6-116. eCollection 2014. Review.

18.

Severity and outcome of cystic lung disease in women with tuberous sclerosis complex.

Taveira-DaSilva AM, Jones AM, Julien-Williams P, Yao J, Stylianou M, Moss J.

Eur Respir J. 2015 Jan;45(1):171-80. doi: 10.1183/09031936.00088314. Epub 2014 Dec 23.

19.

Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.

Yao J, Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J.

Am J Respir Crit Care Med. 2014 Dec 1;190(11):1273-82. doi: 10.1164/rccm.201405-0918OC.

20.

Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.

Taveira-DaSilva AM, Jones AM, Julien-Williams PA, Stylianou M, Moss J.

Chest. 2015 Jan;147(1):180-187. doi: 10.1378/chest.14-0758.

21.

Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.

Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX; MILES Trial Group.

Lancet Respir Med. 2013 Aug;1(6):445-52.

22.

CT grading of lung disease in lymphangioleiomyomatosis.

Yao J, Taveira-DaSilva AM, Colby TV, Moss J.

AJR Am J Roentgenol. 2012 Oct;199(4):787-93.

PMID:
22997369
23.

Optimizing treatments for lymphangioleiomyomatosis.

Taveira-DaSilva AM, Moss J.

Expert Rev Respir Med. 2012 Jun;6(3):267-76. doi: 10.1586/ers.12.26. Review.

24.

Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis.

Harari S, Torre O, Cassandro R, Taveira-DaSilva AM, Moss J.

Respir Med. 2012 Sep;106(9):1286-92. doi: 10.1016/j.rmed.2012.06.012. Epub 2012 Jul 7.

25.

Progress in the treatment of lymphangioleiomyomatosis: from bench to bedside.

Taveira-DaSilva AM, Moss J.

Rev Port Pneumol. 2012 May-Jun;18(3):142-4. doi: 10.1016/j.rppneu.2012.02.005. Epub 2012 Apr 4. No abstract available.

26.

Favorable response to antigonadal therapy for a benign metastasizing leiomyoma.

Taveira-DaSilva AM, Alford CE, Levens ED, Kotz HL, Moss J.

Obstet Gynecol. 2012 Feb;119(2 Pt 2):438-42. doi: 10.1097/AOG.0b013e318240090e.

27.

Prevalence of uterine leiomyomas in lymphangioleiomyomatosis.

Taveira-Dasilva AM, Rabel A, Gochuico BR, Avila NA, Moss J.

Fertil Steril. 2011 Sep;96(3):711-714.e1. doi: 10.1016/j.fertnstert.2011.06.038.

28.

Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J.

Ann Intern Med. 2011 Jun 21;154(12):797-805, W-292-3. doi: 10.7326/0003-4819-154-12-201106210-00007.

29.

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group.

N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.

30.

Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Ikeda Y, Taveira-DaSilva AM, Pacheco-Rodriguez G, Steagall WK, El-Chemaly S, Gochuico BR, May RM, Hathaway OM, Li S, Wang JA, Darling TN, Stylianou M, Moss J.

Am J Physiol Lung Cell Mol Physiol. 2011 Jan;300(1):L64-72. doi: 10.1152/ajplung.00095.2010. Epub 2010 Oct 29.

31.

The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J.

Lymphat Res Biol. 2010 Mar;8(1):9-19. doi: 10.1089/lrb.2009.0024.

32.

Reversible airflow obstruction in lymphangioleiomyomatosis.

Taveira-DaSilva AM, Steagall WK, Rabel A, Hathaway O, Harari S, Cassandro R, Stylianou M, Moss J.

Chest. 2009 Dec;136(6):1596-1603. doi: 10.1378/chest.09-0624. Epub 2009 May 15. Erratum in: Chest. 2010 Mar;137(3):744.

33.

Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis.

Taveira-DaSilva AM, Burstein D, Hathaway OM, Fontana JR, Gochuico BR, Avila NA, Moss J.

Chest. 2009 Sep;136(3):665-670. doi: 10.1378/chest.08-3034. Epub 2009 Mar 24.

34.

Lymphangioleiomyomatosis.

Taveira-DaSilva AM, Steagall WK, Moss J.

Atlas Genet Cytogenet Oncol Haematol. 2009;13(10):751-757. No abstract available.

35.

Therapeutic options for lymphangioleiomyomatosis (LAM): where we are and where we are going.

Taveira-Dasilva AM, Steagall WK, Moss J.

F1000 Med Rep. 2009 Dec 9;1. pii: 93. doi: 10.3410/M1-93.

36.

Lymphatic involvement in lymphangioleiomyomatosis.

Glasgow CG, Taveira-Dasilva AM, Darling TN, Moss J.

Ann N Y Acad Sci. 2008;1131:206-14. doi: 10.1196/annals.1413.018. Review.

37.

Computer-Aided Grading of Lymphangioleiomyomatosis (LAM) using HRCT.

Yao J, Avila N, Dwyer A, Taveira-Dasilva AM, Hathaway OM, Moss J.

Proc IAPR Int Conf Pattern Recogn. 2008 Jan 23;2008(8-11 Dec. 2008):1-4.

38.

Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.

Harari S, Cassandro R, Chiodini I, Taveira-DaSilva AM, Moss J.

Chest. 2008 Feb;133(2):448-54. Epub 2007 Dec 10. Erratum in: Chest. 2009 Aug 1;136(2):653. Chiodini, Jacopo [corrected to Chiodini, Iacopo].

39.

Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study.

Taveira-DaSilva AM, Hathaway OM, Sachdev V, Shizukuda Y, Birdsall CW, Moss J.

Chest. 2007 Nov;132(5):1573-8. Epub 2007 Sep 21.

40.

Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis.

Steagall WK, Glasgow CG, Hathaway OM, Avila NA, Taveira-Dasilva AM, Rabel A, Stylianou MP, Lin JP, Chen X, Moss J.

Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L800-8. Epub 2007 Jul 6.

41.

Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension.

Anthi A, Machado RF, Jison ML, Taveira-Dasilva AM, Rubin LJ, Hunter L, Hunter CJ, Coles W, Nichols J, Avila NA, Sachdev V, Chen CC, Gladwin MT.

Am J Respir Crit Care Med. 2007 Jun 15;175(12):1272-9. Epub 2007 Mar 22.

42.

Lymphangioleiomyomatosis.

Taveira-DaSilva AM, Steagall WK, Moss J.

Cancer Control. 2006 Oct;13(4):276-85. Review.

PMID:
17075565
43.

N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.

Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, Taveira-DaSilva AM, Ballas SK, Blackwelder W, Xu X, Hunter L, Barton B, Waclawiw M, Castro O, Gladwin MT; MSH Investigators.

JAMA. 2006 Jul 19;296(3):310-8.

PMID:
16849664
44.

Clinical and molecular insights into lymphangioleiomyomatosis.

Steagall WK, Taveira-DaSilva AM, Moss J.

Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S49-66. Review.

PMID:
16457017
45.

Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J.

Chest. 2004 Dec;126(6):1867-74.

PMID:
15596686
46.

Bone mineral density in lymphangioleiomyomatosis.

Taveira-Dasilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J.

Am J Respir Crit Care Med. 2005 Jan 1;171(1):61-7. Epub 2004 Oct 1.

PMID:
15466255
47.

Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis.

Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Kristof AS, Avila NA, Rabel A, Travis WD, Moss J.

Am J Respir Crit Care Med. 2003 Dec 15;168(12):1427-31. Epub 2003 Sep 4.

PMID:
12958050
48.

Serotonin 1A receptor agonists reverse respiratory abnormalities in spinal cord-injured rats.

Teng YD, Bingaman M, Taveira-DaSilva AM, Pace PP, Gillis RA, Wrathall JR.

J Neurosci. 2003 May 15;23(10):4182-9.

49.

Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis.

Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, Moss J.

Am J Respir Crit Care Med. 2001 Sep 15;164(6):1072-6.

PMID:
11587999
50.

Reversal of morphine-induced apnea in the anesthetized rat by drugs that activate 5-hydroxytryptamine(1A) receptors.

Sahibzada N, Ferreira M, Wasserman AM, Taveira-DaSilva AM, Gillis RA.

J Pharmacol Exp Ther. 2000 Feb;292(2):704-13.

PMID:
10640309

Supplemental Content

Loading ...
Support Center